I don't think the existence of rare costly outcomes is very good evidence that anything is wrong with the system.
Among high-level players, the vast majority of poker hands ends with an "agreement" about who probably has the strongest hand (i.e, all but one player folds and there's a modest transfer of funds to that player). But in order for that system to work, there has to be a credible threat of a showdown which, from an economic perspective considering just that single hand, is inefficient.
Likewise, the patent system might be good or bad overall, but occasional occurance of costly outcomes doesn't tell us much.
That’s literally what Massimo wanted, before Apple bailed on the partnership and poached their employees instead…
Patent law is there, because creating original work is costly and can take years in engineering and scientific fields. The patents are there to give a time-window for the people who made the investments to make their money back and get some return on their investment.
The issue here is not that Apple hired them or that Apple didn’t go through with the deal. The issue is that Apple didn’t innovate but instead infringed on someone else’s IP. If you want to see an example of what Apple should have done, go check out the Garmin patents around pulseox.
Edit: People like to dunk on Garmin for being slow to market, while ignoring the degree to which Garmin doesn’t just rip off patented ideas and instead actually innovates.
[^1] https://www.masimopersonalhealth.com/products/masimo-w1
Perhaps the public should buy the Masimo watch if they appreciate the specific advantages of the specific pulse oximetry technology at question here. While that may satisfy a small percentage of customers whose primary motive is that specific feature, the majority of people I know wouldn't consider that a valid option, since they like the integration with the "apple ecosystem", or similar reasons.
Would it be possible to separate end products from component technology in a way that prevents this? Perhaps by tracking an accounting line for patents internally, then pushing for legislation which requires patent-cost -> end product cost transparency?